CD274 and neoplasm: Experience from a series of clinical trials across a variety of tumor types suggests that although PD-L1 positivity is associated with a greater likelihood of response from anti-PD-1 or anti-PD-L1 agents, the benefit is not restricted to the PD-L1-positive population exclusively [18].